News
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a
Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a
Aruvant Appoints William Chou as Chief Executive Officer
Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe
Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens Both patients exhibit evidence of sustained, stable, genetically-modified cells in blood and
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children’s Hospital Medical Center
BASEL, Switzerland and CINCINNATI November 26, 2018 | PRNewswire Roivant Sciences and Cincinnati Children’s Hospital Medical Center today announced the launch of Aruvant Sciences, a